Your browser of choice has not been tested for use with Barchart.com. If you have issues, please download one of the browsers listed here.
Stocks | Futures | Watchlist | More
or

Ocular Therapeut (OCUL)

Ocular Therapeut (OCUL)

[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] by (Cboe BZX)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] [[ item.lastPriceExt ]] [[ item.priceChangeExt ]] ([[ item.percentChangeExt ]]) [[ item.tradeTimeExt ]]
Quote Overview for [[ item.sessionDateDisplayLong ]]
[[ rowChartData.labelLow ]]
[[ rowChartData.lowPriceFormatted ]]
[[ rowChartData.lowPrice ]]
[[ rowChartData.labelHigh ]]
[[ rowChartData.highPriceFormatted ]]
[[ rowChartData.highPrice ]]
since [[ rowChartData.lowDate ]]
since [[ rowChartData.highDate ]]
[[ value ]] [[ value ]]
Realtime quote and/or trades are not sourced from all markets.

Fundamentals

See More
  • Market Capitalization, $K 258,679
  • Shares Outstanding, K 52,577
  • Annual Sales, $ 4,230 K
  • Annual Income, $ -86,370 K
  • 60-Month Beta 2.03
  • Price/Sales 60.70
  • Price/Cash Flow N/A
  • Price/Book N/A

Analyst Rating / Earnings Estimates

Current Rating
See More
Strong Buy
Based on 6 analysts offering recommendations.
Earnings Estimates - Current Qtr 03/31/20
See More
  • Average Estimate -0.37
  • Number of Estimates 3
  • High Estimate -0.29
  • Low Estimate -0.43
  • Prior Year -0.45
  • Growth Rate Est. (year over year) +17.78%

Price Performance

See More
Period Period Low Period High Performance
1-Month
3.78 +31.13%
on 03/13/20
8.12 -39.04%
on 03/05/20
+0.24 (+5.21%)
since 02/28/20
3-Month
3.78 +31.13%
on 03/13/20
8.12 -39.04%
on 03/05/20
+0.76 (+18.14%)
since 12/27/19
52-Week
2.35 +110.64%
on 05/21/19
8.12 -39.04%
on 03/05/20
+0.98 (+24.69%)
since 03/29/19

Most Recent Stories

More News
Ocular Therapeutix (OCUL) Reports Q4 Loss, Misses Revenue Estimates

Ocular Therapeutix (OCUL) delivered earnings and revenue surprises of -11.90% and -1.91%, respectively, for the quarter ended December 2019. Do the numbers hold clues to what lies ahead for the stock?

OCUL : 4.95 (+0.61%)
Ocular Therapeutix: 4Q Earnings Snapshot

BEDFORD, Mass. (AP) _ Ocular Therapeutix Inc. (OCUL) on Thursday reported a loss of $26 million in its fourth quarter.

OCUL : 4.95 (+0.61%)
Ocular Therapeutix(TM) Reports Fourth Quarter and Year End 2019 Financial Results and Business Update

--Presented Interim Clinical Data Releases for OTX-TIC and OTX-TKI Showing Favorable Safety Profile, Tolerability, Durability and Early Biological Activity

OCUL : 4.95 (+0.61%)
Ocular Therapeutix, Inc. to Host Earnings Call

NEW YORK, NY / ACCESSWIRE / March 12, 2020 / Ocular Therapeutix, Inc. (NASDAQ:OCUL) will be discussing their earnings results in their 2019 Fourth Quarter Earnings call to be held on March 12, 2020 at...

OCUL : 4.95 (+0.61%)
Global Ocular Drug Delivery Technology Market By New Business Developments - Forecast To 2029| Valeant Pharmaceuticals International Inc, Clearside Biomedical Inc and Alimera Sciences Inc

Global Ocular Drug Delivery Technology Market (Revenue and Volume), Type, Application, End-User, and Regional Analysis, Import-Export Analysis, Industry Analysis, Premium Insights, Intellectual Property...

ALIM : 3.61 (-17.77%)
AGN : 176.31 (+1.91%)
CLSD : 1.7600 (+1.15%)
NVS : 81.90 (+3.30%)
OCUL : 4.95 (+0.61%)
PFE : 32.67 (+5.73%)
VRX.TO : 30.80 (-3.33%)
Ocular Therapeut is Among the Companies in the Pharmaceuticals Industry with the Best Relative Performance (OCUL , XENT , LLY , ITCI , PRGO )

We looked at the Pharmaceuticals industry and measured relative performance to find the top stocks. Relative outperformance is a bullish sign of underlying fundamental and technical strength. We look...

LLY : 138.44 (+3.23%)
XENT : 11.64 (-4.98%)
OCUL : 4.95 (+0.61%)
Ocular Therapeutix(TM) To Report Fourth Quarter and Year-End 2019 Financial Results

Ocular Therapeutix(TM), Inc. (NASDAQ: OCUL), a biopharmaceutical company focused on the formulation, development, and commercialization of innovative therapies for diseases and conditions of the eye, today...

OCUL : 4.95 (+0.61%)
Ocular Therapeutix(TM) Announces Preliminary Fourth Quarter 2019 Net Product Revenue and Provides Update on Interim Data from the OTX-TKI Phase 1 Clinical Trial at the Cowen 40th Annual Health Care Conference

Ocular Therapeutix(TM), Inc. (NASDAQ: OCUL), a biopharmaceutical company focused on the formulation, development, and commercialization of innovative therapies for diseases and conditions of the eye, today...

OCUL : 4.95 (+0.61%)
Analysts Estimate Ocular Therapeutix (OCUL) to Report a Decline in Earnings: What to Look Out for

Ocular Therapeutix (OCUL) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.

OCUL : 4.95 (+0.61%)
Ocular Therapeutix(TM) to Present at the Cowen and Company 40th Annual Health Care Conference

Ocular Therapeutix(TM), Inc. (NASDAQ: OCUL), a biopharmaceutical company focused on the formulation, development, and commercialization of innovative therapies for diseases and conditions of the eye, today...

OCUL : 4.95 (+0.61%)

Barchart Technical Opinion

The Barchart Technical Opinion rating is a 56% Buy with a Average short term outlook on maintaining the current direction.

Long term indicators fully support a continuation of the trend.

See More Share

Trade OCUL with:

Business Summary

Ocular Therapeutix, Inc. is a biopharmaceutical company. It is focused on the development and commercialization of ophthalmic therapeutic products using its proprietary hydrogel technology to address unmet or underserved needs in ophthalmology. The Company develops and markets eye care products. Ocular...

See More

Key Turning Points

2nd Resistance Point 5.45
1st Resistance Point 5.19
Last Price 4.95
1st Support Level 4.66
2nd Support Level 4.39

See More

52-Week High 8.12
Fibonacci 61.8% 5.92
Fibonacci 50% 5.23
Last Price 4.95
Fibonacci 38.2% 4.55
52-Week Low 2.35

See More

Want to use this as
your default charts setting?
Learn about our Custom Templates
Switch the Market flag
above for targeted data.
Open the menu and switch the
Market flag for targeted data.
Get Streaming Chart Updates
Switch your Site Preferences
to Interactive Chart
Need More Chart Options?
Right-click on the chart to open the Interactive Chart menu.

Free Barchart Webinar